Giorgio G. Inghirami

Dec 5, 2024 | cell.com | Yusuke Isshiki |Xi Chen |Matt Teater |Ioannis Karagiannidis |Winson Cai |Cem Meydan | +18 more

KeywordsEZH2T cell immunotherapyCAR-Tbispecific antibodiesfollicular lymphomaDLBCLGet full text accessLog in, subscribe or purchase for full access. References1. Schuster, S.J. ∙ Svoboda, J. ∙ Chong, E.A. ... Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasN. Engl. J. Med. 2017; 377:2545-25542. Locke, F.L. ∙ Miklos, D.B. ∙ Jacobson, C.A. ... Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaN. Engl. J. Med. 2022; 386:640-6543. Bishop, M.R. ∙ Dickinson, M. ∙ Purtill, D. ...

Jul 30, 2024 | nature.com | Giorgio G. Inghirami |Olivier Elemento

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, and over 60% patients can achieve durable remission after receiving standard immunotherapy treatment that comprises rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) [1,2,3]. The remaining patients are refractory to this frontline treatment or suffer tumor relapses with an extremely poor prognosis [4].